Article Access statistics

Viewed: 918

Emailed: 0

PDF Downloaded: 270

IP International Journal of Orthopaedic Rheumatology

Interleukin-6 blocker for successful outcome of late-onset rheumatoid oligoarthritis

Full Text PDF Share on Facebook Share on Twitter

Author Details : Yuva Vishalini Ravindran, Subramanian Nallasivan

Volume : 3, Issue : 1, Year : 2017

Article Page : 35-36

Suggest article by email


Newer cytokine therapies have revolutionised the management of Rheumatoid arthritis. Atypical oligoarthritis can also be a manifestation of RA and CCP antibodies have been proven to be most specific for Rheumatoid. Our patient had 2 years of painful ankle bilaterally and suggested for joint replacement due to osteoarthritis changes. After the diagnosis of RA using Anti-CCP antibodies, we elected to give Tocilizumab(IL 6 Blocker) which had made the patient to walk without wheelchair after 2 years. This suggests early appropriate diagnosis is the key and Biologics- the new Kid in the market- has proven to be effective in early Rheumatoid arthritis.

Tocilizumab, Oligoarthitis, IL-6 blocker, Anti-CCP antibodies, Rheumatoid arthritis

How to cite : Ravindran Y V, Nallasivan S, Interleukin-6 blocker for successful outcome of late-onset rheumatoid oligoarthritis. IP Int J Orthop Rheumatol 2017;3(1):35-36

Copyright © 2017 by author(s) and IP Int J Orthop Rheumatol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (